Craig R. RaynerCertara Distinguished Scientist
Dr. Rayner is Certara Distinguished Scientist. In this capacity, he leads key strategic client engagements and scientific innovation.
Craig has extensive global experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities.
Previously, Craig was the Co-founder and CEO of d3 Medicine. Prior to that, Craig’s appointments included leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche), and in clinical pharmacology and infectious disease research (Monash University).
Craig holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), is a Distinguished Alumni of the Faculty of Pharmacy and Pharmaceutical Sciences (Monash University), has broadly published in clinical pharmacology and also infectious diseases.